Literature DB >> 9364784

Vaccination and the population structure of antigenically diverse pathogens that exchange genetic material.

S Gupta1, N M Ferguson, R M Anderson.   

Abstract

Populations of antigenically diverse pathogens undergoing genetic exchange may be categorized into strains on the basis of a set of principal protective antigens. The extent to which polyvalent vaccines based on these protective antigens can alter the population structure of the pathogen is determined by the degree of cross-protection between strains. In the case where there is no cross-protection, vaccinating against a particular strain will have no effect on the others. As cross-protection increases, the strains containing the antigenic variants included in the vaccine will be diminished in prevalence, and those that do not will increase in prevalence. The rise in prevalence of the latter will become more and more exaggerated as cross-protection increases. However, beyond a critical level of cross-protection, in the absence of vaccination, the steady state of the system is asymmetric in that a certain subset of strains (with non-overlapping repertoires of antigenic variants) will dominate over the others in terms of prevalence. Under these circumstances, a vaccine consisting of the most immunogenic combinations of antigenic variants can cause a dramatic increase in frequency of a subset of rare strains.

Mesh:

Substances:

Year:  1997        PMID: 9364784      PMCID: PMC1688705          DOI: 10.1098/rspb.1997.0200

Source DB:  PubMed          Journal:  Proc Biol Sci        ISSN: 0962-8452            Impact factor:   5.349


  9 in total

1.  Vaccination against colonizing bacteria with multiple serotypes.

Authors:  M Lipsitch
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

2.  A competitive exclusion principle for pathogen virulence.

Authors:  H J Bremermann; H R Thieme
Journal:  J Math Biol       Date:  1989       Impact factor: 2.259

3.  Epidemiology and genetics in the coevolution of parasites and hosts.

Authors:  R M May; R M Anderson
Journal:  Proc R Soc Lond B Biol Sci       Date:  1983-10-22

4.  The maintenance of strain structure in populations of recombining infectious agents.

Authors:  S Gupta; M C Maiden; I M Feavers; S Nee; R M May; R M Anderson
Journal:  Nat Med       Date:  1996-04       Impact factor: 53.440

5.  Theoretical studies of the effects of heterogeneity in the parasite population on the transmission dynamics of malaria.

Authors:  S Gupta; J Swinton; R M Anderson
Journal:  Proc Biol Sci       Date:  1994-06-22       Impact factor: 5.349

6.  Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein.

Authors:  P Van Der Ley; J T Poolman
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

7.  T cell recognition of Neisseria meningitidis class 1 outer membrane proteins. Identification of T cell epitopes with selected synthetic peptides and determination of HLA restriction elements.

Authors:  E J Wiertz; J A van Gaans-van den Brink; G M Schreuder; A A Termijtelen; P Hoogerhout; J T Poolman
Journal:  J Immunol       Date:  1991-09-15       Impact factor: 5.422

8.  Comparison of the class 1 outer membrane proteins of eight serological reference strains of Neisseria meningitidis.

Authors:  M C Maiden; J Suker; A J McKenna; J A Bygraves; I M Feavers
Journal:  Mol Microbiol       Date:  1991-03       Impact factor: 3.501

Review 9.  Pneumococcal virulence factors and host immune responses to them.

Authors:  D A Watson; D M Musher; J Verhoef
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-06       Impact factor: 3.267

  9 in total
  11 in total

1.  Vaccination and the dynamics of immune evasion.

Authors:  Olivier Restif; Bryan T Grenfell
Journal:  J R Soc Interface       Date:  2007-02-22       Impact factor: 4.118

2.  The evolutionary consequences of alternative types of imperfect vaccines.

Authors:  Krisztian Magori; Andrew W Park
Journal:  J Math Biol       Date:  2013-02-28       Impact factor: 2.259

3.  Vaccination can drive an increase in frequencies of antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae.

Authors:  Uri Obolski; José Lourenço; Craig Thompson; Robin Thompson; Andrea Gori; Sunetra Gupta
Journal:  Proc Natl Acad Sci U S A       Date:  2018-03-06       Impact factor: 11.205

4.  No coexistence for free: neutral null models for multistrain pathogens.

Authors:  Marc Lipsitch; Caroline Colijn; Ted Cohen; William P Hanage; Christophe Fraser
Journal:  Epidemics       Date:  2008-11-04       Impact factor: 4.396

5.  Meiotic recombination, cross-reactivity, and persistence in Plasmodium falciparum.

Authors:  F E McKenzie; M U Ferreira; J K Baird; G Snounou; W H Bossert
Journal:  Evolution       Date:  2001-07       Impact factor: 3.694

6.  Effects of epistasis and recombination between vaccine-escape and virulence alleles on the dynamics of pathogen adaptation.

Authors:  David V McLeod; Sylvain Gandon
Journal:  Nat Ecol Evol       Date:  2022-04-18       Impact factor: 19.100

7.  Short report: rare Plasmodium falciparum merozoite surface protein 1 19-kda (msp-1(19)) haplotypes identified in Mali using high-throughput genotyping methods.

Authors:  Shannon L Takala; David L Smith; Mahamadou A Thera; Drissa Coulibaly; Ogobara K Doumbo; Christopher V Plowe
Journal:  Am J Trop Med Hyg       Date:  2007-05       Impact factor: 2.345

8.  Sex allocation and population structure in apicomplexan (protozoa) parasites.

Authors:  S A West; T G Smith; A F Read
Journal:  Proc Biol Sci       Date:  2000-02-07       Impact factor: 5.349

9.  Vaccination Drives Changes in Metabolic and Virulence Profiles of Streptococcus pneumoniae.

Authors:  Eleanor R Watkins; Bridget S Penman; José Lourenço; Caroline O Buckee; Martin C J Maiden; Sunetra Gupta
Journal:  PLoS Pathog       Date:  2015-07-16       Impact factor: 6.823

Review 10.  Virulence evolution in response to vaccination: the case of malaria.

Authors:  M J Mackinnon; S Gandon; A F Read
Journal:  Vaccine       Date:  2008-07-18       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.